AGORACOM News Flash

AGORACOM WIRE - WEDNESDAY MAY 30TH, 2012

GOLDEN HOPE MINES (TSXV:GNH) Confirms High Grade Intersection of 64.1 g/t Au (Gold) over 1m Read More

The screen metallic analysis returned 82 g/t Au for an average grade of 93.5 g/t Au.
Two additional fire assays on the original pulp done prior to the screen metallic analyses returned 0.22 g/t Au and 0.12 g/t Au for an average fire assay grade of 0.41 g/t Au. The weighted average of all the fire assays and screen metallic assays from this 1-metre section in hole BD2011-184 is 64.1 g/t Au.

Sonomax® eers™ Custom Earbuds Announces Sponsorship of MUTEK 2012

Mutek provides an essential platform for 150 performers to showcase forward-thinking electronic music programming and new media to more than 25,000 attendees
Read Full Press Release; Read Why Sonomax?
Jump Into Active Discussion Forum
*Sponsor*

CONTINENTAL ENERGY Geothermal Energy Project Receives US$ 11.5 Million Grant Read More * Client

AGORACOM Launches Graphite Stocks Blog

Filed Notice of Intention to Make a Proposal Under the Bankruptcy & Insolvency

posted on Apr 15, 09 01:11AM

April 14, 2009

PharmEng Has Filed Notice of Intention to Make a Proposal Under the Bankruptcy & Insolvency Act (Canada)

TORONTO, ONTARIO--(Marketwire - April 14, 2009) - PharmEng International Inc. (TSX VENTURE:PII) together with certain of its wholly-owned subsidiaries (collectively, the "Company" or "PharmEng"), today announced that it has filed a Notice of Intention ("NOI") to make a Proposal under the Bankruptcy & Insolvency Act (Canada) (the "BIA").

The Company also announces that notices of default have been provided to the Company as of April 9, 2009 and April 13, 2009 in relation to two of its credit obligations for an aggregate of approximately $7 million. One of the Company's creditors, BHC Interim Funding II, L.P. has provided notice to the Company that it elects to exercise its voting power pursuant to a stock pledge agreement that it entered into with the Company dated December 21, 2007. The Company is also in default under its credit facility and term loan with Landsbanki Islands h.f. in the aggregate amount of approximately $14 million.

A. Farber & Partners Inc., a licensed trustee, has accepted its appointment as trustee under the Proposal of the Company. Further information about the proceedings will be available later today on Trustee's web site at www.afarber.com.

PharmEng's day-to-day operations will continue uninterrupted throughout the NOI process while the Company undertakes to restructure and implement a plan of reorganization of the Company. The objective of filing the NOI is to regain the Company's financial footing. Of paramount importance to the Company is to retain its customers throughout the process by providing no disruption to service levels.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. To find our more about PharmEng International Inc. (TSX-V: PII), visit our website at www.pharmeng.com.